Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]
J Saudi Heart AssocAlHabeeb W +12 more
europepmc +1 more source
Non-Responder to Inclisiran and Evolocumab-A Female Patient with Heterozygous Familial Hypercholesterolemia and Statin Intolerance. [PDF]
DiseasesMuszyński P +7 more
europepmc +1 more source
Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients. [PDF]
Circ RepTsuda S, Yamada S, Yoshida A.
europepmc +1 more source
Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]
JACC AdvBlais JE +4 more
europepmc +1 more source
Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation. [PDF]
Chin Med J (Engl)Jiang Q, Fu J, An Y, Liu Y.
europepmc +1 more source
Long-Acting Lipid-Lowering Injectables and Behavioral Moral Hazard: A Systematic Review of Adherence, Lifestyle Measurement, and Structural Evidence Gaps. [PDF]
Healthcare (Basel)Cumpăt CM +5 more
europepmc +1 more source
RNA-Based Therapies for Hypercholesterolemia and Coronary Artery Disease. [PDF]
CureusLopez Mendoza MJ +5 more
europepmc +1 more source
Intensive lipid-lowering therapy-related regression of a vulnerable plaque confirmed by serial optical coherence tomography: a case report. [PDF]
Front Cardiovasc MedQu J +6 more
europepmc +1 more source
Evaluating Value Beyond Efficacy: A Meta-Analytic Assessment of Inclisiran's Cost-Effectiveness in Cardiovascular Prevention. [PDF]
Healthcare (Basel)Maștaleru A +6 more
europepmc +1 more source